Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salivary LDH and CRP changes after prednisolone therapy in erosive oral lichen planus
IRCT20160126026209N2Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of prednisolone in oral lichen planus (OLP), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Salivary lactate dehydrogenase and Salivary C-reactive protein. Started May 2022; status: completed.
02
Drugs
prednisolone
03
Conditions
oral lichen planus (OLP)
Beyond the preview
Go deeper on IRCT20160126026209N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160126026209N2.